Leyden Labs

Shaping the Future of Vaccines and Infectious Disease Solutions

Mastering Mucosal Immunity: Netherlands and Singapore-based biotech, Leyden Labs, specializes in targeted antibody delivery via nasal sprays to stop viral infections at the point of entry – the nasal mucosa.
Universal Defense Against Respiratory Viruses: Focused on broad and enduring protection against evolving respiratory viruses, Leyden Labs is developing novel therapies such as, PanFlu™, which targets conserved viral regions to ensure long-term effectiveness against new strains. By harnessing this approach, Leyden Labs aims to create self-administered, accessible treatments that provide patients with immediate autonomous protection against both current and future viral threats.
Expert Insights from Leyden Labs’ CEO: Leyden Labs CEO, Koenraad Wiedhaup, can speak on a wide range of topics, including: the future of vaccines for broader infectious diseases, the evolving biotech landscape in Europe, preparing for the next global pandemic, leading international biotech operations, navigating the complexities of biotech financing and more.